Trials Sponsors Conditions Drugs Pricing

Conditions

Alopecia Areata

Outcome Measures

Primary Outcomes (1)

Mean Change in Cortisol Levels From Baseline to Week 24
Mean change in cortisol levels from baseline to week 24 after four triamcinolone acetonide 10 ml injections 6 weeks apart.
baseline, week 24

Study Arms (1)

1

EXPERIMENTAL

Patients receiving Triamcinolone Acetonide 10 ml (Kenalog-10) intralesional injections.

Drug: Triamcinolone Acetonide 10 mg/mL (Kenalog-10)

Interventions

Triamcinolone Acetonide 10 mg/mL (Kenalog-10)Drug

Triamcinolone Acetonide 10 mg/ml (Kenalog-10) intralesional injection

Also known as: Kenalog 10

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Subject has clinical diagnosis of alopecia areata.
Written informed consent and HIPAA authorization have been obtained.

Sponsors & Collaborators

National Alopecia Areata Foundation
Othercollaborator
University of Minnesota
Otherlead

Study Sites (1)

University of Minnesota

Minneapolis, Minnesota, 55455, United States

MeSH Terms

Conditions

Alopecia Areata

Interventions

Triamcinolone AcetonideTriamcinolone

Condition Hierarchy (Ancestors)

AlopeciaHypotrichosisHair DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

PregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic Compounds

Results Point of Contact

Title: Maria Hordinsky, MD
Organization: University of Minnesota

Study Officials

Maria K Hordinsky, MD
University of Minnesota
STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee: Yes
Restrictive Agreement: No

Enrollment

18 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 2
Allocation: NA
Masking: NONE
Purpose: SCREENING
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

June 8, 2007

First Posted

June 11, 2007

Study Start

May 2007

Date type not reported

This date has not been verified as actual or estimated.

Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Results Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

1

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Results Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

1

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations